Difference between revisions of "Team:Lethbridge HS/Description"
Rossoliver (Talk | contribs) |
18desilvni (Talk | contribs) |
||
| Line 895: | Line 895: | ||
</div> | </div> | ||
<div class="col-md-11> | <div class="col-md-11> | ||
| − | |||
<a name="first"></a> | <a name="first"></a> | ||
| − | + | <h3>Background Information<h3/> | |
<p><br>This year our team has decided to focus on increasing the speed and overall efficiency of blood coagulation in medium to large sized wounds. Although there are other products currently available in the market to increase the rate of blood coagulation, such as Quikclot (Z-Medica, 2014), or VetiGel (Bloomberg, 2014), our product is significantly different from these. Our product, called “Coagu.coli”, is based on using a component from the snake venom of the Desert Horned Viper (Cerastes cerastes). Certain components of snake venoms are able to bypass several steps of the blood clotting cascade, therefore increasing the speed of blood clotting (Braud, 2000; Castro, Zingali, Albuquerque, Pujol-Luz, & Rodrigues, 2004). The component we are utilizing is Cerastotin and this is a serine protease that has thrombin like properties. What sets Cerastotin apart from other serine proteases is that it is easy to express and small enough to be used in our construct. Thrombin is an enzyme that causes the conversion of fibrinogen to fibrin, which leads to the formation of a clot (Smith, 1980; Wolberg, 2007). By using Cerastotin in our construct, we are therefore able to greatly increase the efficiency and speed of blood coagulation. Our product would be applied by a syringe containing our construct followed by a bandage for sealing it in place, and could be used in a variety of situations. Because our product would be produced in E.Coli, it would be highly affordable as a great amount can be expressed in a short period of time. The military, hospitals, and the average person would find our product invaluable. Coagu.coli has the power to prevent death by severe blood loss by giving a person enough time to receive further medical attention.<br/></p> | <p><br>This year our team has decided to focus on increasing the speed and overall efficiency of blood coagulation in medium to large sized wounds. Although there are other products currently available in the market to increase the rate of blood coagulation, such as Quikclot (Z-Medica, 2014), or VetiGel (Bloomberg, 2014), our product is significantly different from these. Our product, called “Coagu.coli”, is based on using a component from the snake venom of the Desert Horned Viper (Cerastes cerastes). Certain components of snake venoms are able to bypass several steps of the blood clotting cascade, therefore increasing the speed of blood clotting (Braud, 2000; Castro, Zingali, Albuquerque, Pujol-Luz, & Rodrigues, 2004). The component we are utilizing is Cerastotin and this is a serine protease that has thrombin like properties. What sets Cerastotin apart from other serine proteases is that it is easy to express and small enough to be used in our construct. Thrombin is an enzyme that causes the conversion of fibrinogen to fibrin, which leads to the formation of a clot (Smith, 1980; Wolberg, 2007). By using Cerastotin in our construct, we are therefore able to greatly increase the efficiency and speed of blood coagulation. Our product would be applied by a syringe containing our construct followed by a bandage for sealing it in place, and could be used in a variety of situations. Because our product would be produced in E.Coli, it would be highly affordable as a great amount can be expressed in a short period of time. The military, hospitals, and the average person would find our product invaluable. Coagu.coli has the power to prevent death by severe blood loss by giving a person enough time to receive further medical attention.<br/></p> | ||
<h3>References</h3> | <h3>References</h3> | ||
Revision as of 03:02, 19 October 2016
Background Information
This year our team has decided to focus on increasing the speed and overall efficiency of blood coagulation in medium to large sized wounds. Although there are other products currently available in the market to increase the rate of blood coagulation, such as Quikclot (Z-Medica, 2014), or VetiGel (Bloomberg, 2014), our product is significantly different from these. Our product, called “Coagu.coli”, is based on using a component from the snake venom of the Desert Horned Viper (Cerastes cerastes). Certain components of snake venoms are able to bypass several steps of the blood clotting cascade, therefore increasing the speed of blood clotting (Braud, 2000; Castro, Zingali, Albuquerque, Pujol-Luz, & Rodrigues, 2004). The component we are utilizing is Cerastotin and this is a serine protease that has thrombin like properties. What sets Cerastotin apart from other serine proteases is that it is easy to express and small enough to be used in our construct. Thrombin is an enzyme that causes the conversion of fibrinogen to fibrin, which leads to the formation of a clot (Smith, 1980; Wolberg, 2007). By using Cerastotin in our construct, we are therefore able to greatly increase the efficiency and speed of blood coagulation. Our product would be applied by a syringe containing our construct followed by a bandage for sealing it in place, and could be used in a variety of situations. Because our product would be produced in E.Coli, it would be highly affordable as a great amount can be expressed in a short period of time. The military, hospitals, and the average person would find our product invaluable. Coagu.coli has the power to prevent death by severe blood loss by giving a person enough time to receive further medical attention.
References
Bloomberg (2014, November 18). VetiGel: The band-aid of the future stops bleeding instantlyRetrieved from https://www.youtube.com/watch?v=dJLxRcU9No4
Braud, S. (2000). Snake venom proteins acting on hemostasis. Biochimie, 82(9-10), 851–859. doi:10.1016/s0300-9084(00)01178-0
Castro, H. C., Zingali, R. B., Albuquerque, M. G., Pujol-Luz, M., & Rodrigues, C. R. (2004). Snake venom thrombin-like enzymes: From reptilase to now. Cellular and Molecular Life Sciences (CMLS),61(7-8), 843–856. doi:10.1007/s00018-003-3325-z
Smith, G. F. (1980). Fibrinogen–fibrin conversion. The mechanism of fibrin-polymer formation in solution. Biochemical Journal, 185(1), 1–11. doi:10.1042/bj1850001
Wolberg, A. S. (2007). Thrombin generation and fibrin clot structure. Blood Reviews, 21(3), 131–142. doi:10.1016/j.blre.2006.11.001
Z-Medica. (2014). QuikClot® - stop bleeding fast. Retrieved October 16, 2016, from http://www.quikclot.com/
